| 1 |
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz et al. · New England Journal of Medicine
Open access |
7 Nov 2018 |
3,654 |
| 2 |
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, Mary Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine
Open access |
8 Jun 2015 |
2,619 |
| 3 |
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong, Burkert Mathias Pieske, Kevin Joseph Anstrom et al. · New England Journal of Medicine
Open access |
28 Mar 2020 |
1,350 |
| 4 |
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Renato D. Lópes et al. · New England Journal of Medicine
Open access |
17 Mar 2019 |
1,223 |
| 5 |
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera Bittner et al. · Journal of the American College of Cardiology
Open access |
2020 |
599 |
| 6 |
Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction
Gary Michael Felker, Kevin Joseph Anstrom, Kirkwood F. Adams et al. · JAMA
Open access |
22 Aug 2017 |
554 |
| 7 |
Multi-Centre, Multi-Vendor and Multi-Disease Cardiac Segmentation: The M&Ms Challenge
Victor M. Campello et al. · IEEE Transactions on Medical Imaging
Open access |
17 Jun 2021 |
467 |
| 8 |
Poststroke Aphasia Frequency, Recovery, and Outcomes: A Systematic Review and Meta-Analysis
Heather L. Flowers, Stacey A. Skoretz, Frank L. Silver et al. · Archives of Physical Medicine and Rehabilitation
Review |
9 Apr 2016 |
437 |
| 9 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention
Naveen L. Pereira et al. · JAMA
Open access |
25 Aug 2020 |
424 |
| 10 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz et al. · American Heart Journal
Open access |
6 Aug 2014 |
415 |
| 11 |
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics
Christoph Muus et al. · Nature Medicine
ReviewOpen access235 authors |
Mar 2021 |
379 |
| 12 |
Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction
Justin Adrian Ezekowitz, Padma Kaul, Jeffrey Alexander Bakal et al. · Journal of the American College of Cardiology
Open access |
31 Dec 2008 |
370 |
| 13 |
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Javed Butler et al. · The Lancet
Open access |
Apr 2024 |
364 |
| 14 |
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K Ray et al. · The Lancet Diabetes & Endocrinology
Open access1,703 authors |
Jul 2019 |
332 |
| 15 |
Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis
Nikolaos A. Alexopoulos, Demosthenes G. Katritsis, Paolo Raggi · Atherosclerosis
|
6 Jan 2014 |
331 |
| 16 |
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
Isabelle Johansson et al. · Circulation
Open access |
28 Apr 2021 |
308 |
| 17 |
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease
Ralph Stewart, Claes Held, Nermin Hadziosmanovic et al. · Journal of the American College of Cardiology
Open access |
25 Sep 2017 |
303 |
| 18 |
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions
Stephen John Greene, Johann K Bauersachs, Jasper Jan Brugts et al. · Journal of the American College of Cardiology
Open access |
2023 |
302 |
| 19 |
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Dominick Joseph Angiolillo, Deepak L. Bhatt, Christopher Paul Cannon et al. · Circulation
Open access |
8 Feb 2021 |
302 |
| 20 |
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study
Paul W. Armstrong · European Heart Journal
|
7 Jun 2006 |
299 |
| 21 |
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction
Paul W. Armstrong, Carolyn S.P. Lam, Kevin Joseph Anstrom et al. · JAMA
Open access |
20 Oct 2020 |
290 |
| 22 |
Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia
Jeffrey L. Carson et al. · New England Journal of Medicine
Open access |
11 Nov 2023 |
277 |
| 23 |
The continuous heart failure spectrum: moving beyond an ejection fraction classification
Filippos K. Triposkiadis et al. · European Heart Journal
Open access |
8 Mar 2019 |
267 |
| 24 |
Ferric Carboxymaltose in Heart Failure with Iron Deficiency
Robert John Mentz, Jyotsna Garg, Frank W. Rockhold et al. · New England Journal of Medicine
|
26 Aug 2023 |
244 |
| 25 |
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome
J. Wouter Jukema, Michael J. Szarek, Laurien E. Zijlstra et al. · Journal of the American College of Cardiology
Open access |
18 Mar 2019 |
239 |
| 26 |
The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
Roopinder Kaur Sandhu, Justin Adrian Ezekowitz, Ulrika Andersson et al. · European Heart Journal
Open access |
12 Apr 2016 |
236 |
| 27 |
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure
John R. Teerlink, Gary Michael Felker, John J.V. McMurray et al. · Journal of the American College of Cardiology
Open access |
Mar 2016 |
228 |
| 28 |
Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
Mustafa Toma, Christopher E.H. Buller, Cynthia M. Westerhout et al. · European Heart Journal
|
8 Jun 2010 |
228 |
| 29 |
Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery
Sean van Diepen, Jeffrey Alexander Bakal, Finlay Aleck McAlister et al. · Circulation
|
28 Jun 2011 |
224 |
| 30 |
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael J. Szarek et al. · European Heart Journal
Open access |
24 Jul 2020 |
223 |
| 31 |
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
Darren K. McGuire, Frans Van de Werf, Paul W. Armstrong et al. · JAMA Cardiology
Open access |
13 Apr 2016 |
218 |
| 32 |
Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis
Francesco Borgia, Shaun G. Goodman, Sigrun Halvorsen et al. · European Heart Journal
Review |
2 Jul 2010 |
214 |
| 33 |
The Effectiveness of Pharmacist Interventions on Cardiovascular Risk
Ross T. Tsuyuki, Yazid N. Al Hamarneh, Charlotte Jones et al. · Journal of the American College of Cardiology
Open access |
4 Apr 2016 |
212 |
| 34 |
Cardiovascular Drug Development
Christopher B. Fordyce et al. · Journal of the American College of Cardiology
Open access |
Apr 2015 |
205 |
| 35 |
The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review
Garrison J. B. Dyck, Pema Raj, Shelley R. Zieroth et al. · International Journal of Molecular Sciences
ReviewOpen access |
19 Feb 2019 |
201 |
| 36 |
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer
Thomas Joseph Povsic, Monica G. Lawrence, A. Michael Lincoff et al. · Journal of Allergy and Clinical Immunology
Open access |
16 Jul 2016 |
197 |
| 37 |
Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study
Jasper Tromp, Paul J Seekings, Chung-Lieh Hung et al. · The Lancet Digital Health
Open access |
Dec 2021 |
195 |
| 38 |
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
Gregory G. Schwartz, Philippe Gabríel Steg, Michael J. Szarek et al. · Circulation
Open access |
29 Mar 2020 |
193 |
| 39 |
Role of iron metabolism in heart failure: From iron deficiency to iron overload
Hao Zhang, Pavel Zhabyeyev, Shaohua Wang et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Open access |
26 Aug 2018 |
184 |
| 40 |
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial
Justin Adrian Ezekowitz et al. · The Lancet
Open access |
Apr 2022 |
182 |
| 41 |
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
Michael J. Szarek et al. · Journal of the American College of Cardiology
Open access |
11 Nov 2018 |
175 |
| 42 |
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
Naveen L. Pereira, Charanjit S. Rihal, Ryan J. Lennon et al. · JACC: Cardiovascular Interventions
Open access |
18 Mar 2021 |
170 |
| 43 |
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
Olivia R. Ghosh‐Swaby, Shaun G. Goodman, Lawrence A. Leiter et al. · The Lancet Diabetes & Endocrinology
Review |
22 Apr 2020 |
169 |
| 44 |
Asundexian versus Apixaban in Patients with Atrial Fibrillation
Jonathan Paul Piccini et al. · New England Journal of Medicine
Open access |
Sep 2024 |
163 |
| 45 |
Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure
Antigone Oreopoulos, Justin Adrian Ezekowitz, Finlay Aleck McAlister et al. · Mayo Clinic Proceedings
Open access |
30 Jun 2010 |
158 |
| 46 |
ANHIR: Automatic Non-Rigid Histological Image Registration Challenge
Jiří Borovec et al. · IEEE Transactions on Medical Imaging
Open access |
7 Apr 2020 |
157 |
| 47 |
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
A. Michael Lincoff et al. · The Lancet
|
5 Nov 2015 |
156 |
| 48 |
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Renato D. Lópes et al. · Circulation
Open access155 authors |
30 Aug 2021 |
152 |
| 49 |
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
Meenakshi Sundaram, Sen Zhong, Maroun Bou Khalil et al. · Journal of Lipid Research
Open access |
21 Jul 2009 |
152 |
| 50 |
Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Philippe Gabríel Steg et al. · Circulation
Open access |
23 May 2019 |
150 |